Metabolic and additional vascular effects of thiazolidinediones

Drugs

Volumn 62, Issue 10, 2002, Pages 1463-1480

  Martens, Fabrice M A C ^a   Visseren, Frank L J ^a   Lemay, Jacinthe ^b   de Koning, Eelco J P ^a   Rabelink, Ton J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CD36 ANTIGEN; CELL NUCLEUS RECEPTOR; CHOLESTEROL; FATTY ACID; FIBRIC ACID DERIVATIVE; INSULIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CLINICAL TRIAL; DIABETES CONTROL; DRUG EFFECT; DRUG MARKETING; DRUG MECHANISM; DRUG RECEPTOR BINDING; EDEMA; FATTY ACID BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER TOXICITY; LONG TERM CARE; MULTIGENE FAMILY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PLASMA VOLUME; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; TRANSCRIPTION REGULATION; WEIGHT GAIN;

ANIMALS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; VASODILATION;

EID: 0036076907     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262100-00004     Document Type: Review

References (169)

1. Banting lecture 1988. Role of insulin resistance in human disease
2. The cardiovascular dysmetabolic syndrome
3. Invited commentary: Insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors
4. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers
5. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitis: United Kingdom Prospective Diabetes Study (UKPDS: 23)
6. Medical significance of peroxisome proliferator-activated receptors
7. Peroxisome proliferator activated receptors: A nuclear receptor signaling pathway in lipid physiology
8. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
9. The nuclear receptor superfamily: The second decade
10. The PPARs: From orphan receptors to drug discovery
11. Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation
12. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: Relation to insulin action
13. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: Possible mediators of cardiovascular risk?
14. Peroxisome proliferator-activated receptors in atherosclerosis and inflammation - An update
15. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells
16. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake
17. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma
18. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor
19. Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects
20. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects
21. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes
22. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial
23. Role of glucose and insulin in thiazolidinedione-induced alterations in hepatic gluconeogenesis
24. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action
25. Acute troglitazone action in isolated perfused rat liver
26. Down regulation of peroxisome proliferator-activated receptorgamma expression by inflammatory cytokines and its reversal by thiazolidinediones
27. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat
28. Pioglitazone-induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation
29. The effect of pioglitazone on hepatic glucose uptake measured with indirect and direct methods in alloxan-induced diabetic dogs
30. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-LI cells
31. YM268 increases the glucose uptake, cell differentiation, and mRNA expression of glucose transporter in 3T3-LI adipocytes
32. Actions of novel anti-diabetic thiazolidinedione, T-174, in animal models of non-insulin-dependent diabetes mellitus (NIDDM) and in cultured muscle cells
33. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat
34. TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone
35. Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance
36. A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats
37. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus
38. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled study
39. Troglitazone
40. Efficacy and metabolic effects of metformin and troglitazone in type 11 diabetes mellitus
41. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus
42. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients
43. Rosiglitazone
44. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study
45. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study
46. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
47. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM
48. Peroxisome proliferator-activated receptor (PPAR) gamma: Adipose-predominant expression and induction early in adipocyte differentiation
49. The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability
50. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids
51. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency
52. Peroxisome proliferator-activated receptor-gamma: From adipogenesis to carcinogenesis
53. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor
54. Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPARgamma mRNA expression in 3T3-LI adipocytes
55. Modulation of adipocyte differentiation by tumor necrosis factor and transforming growth factor beta
56. Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance
57. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats
58. The perils of portliness: Causes and consequences of visceral adiposity
59. IGF-I inhibits apoptosis induced by serum withdrawal, but potentiates TNF-alpha-induced apoptosis, in 3T3-LI preadipocytes
60. The hormone resistin links obesity to diabetes
61. Effects of troglitazone on substrate storage and utilization in insulin-resistant rats
62. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats
63. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial
64. Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin
65. Direct regulatory effect of fatty acids on macrophage lipoprotein lipase: Potential role of PPARs
66. Regulatory interactions between lipids and carbohydrates: The glucose fatty acid cycle after 35 years
67. PPARgamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes
68. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL
69. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats
70. CD36 deficiency associated with insulin resistance
71. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors al
72. A single element in the phosphoenolpyruvate carboxykinase gene mediates thiazolidinedione action specifically in adipocytes
73. The mechanisms by which both heterozygous PPARgamma deficiency and PPAR-gamma agonist improve insulin resistance
74. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein
75. Tumor necrosis factor-alpha-induced insulin resistance in 3T3-LI adipocytes is accompanied by a loss of insulin receptor substrate-I and GLUT4 expression without a loss of insulin receptor-mediated signal transduction
76. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function
77. Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha
78. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates
79. Inhibition of tumor necrosis factor-alpha with anti-diabetic agents
80. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling
81. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-gamma
82. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma
83. Impaired vascular reactivity in insulin dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels
84. Dietary modulation of endothelial function: Implications for cardiovascular disease
85. Vascular reactivity
86. A new look at the heart in diabetes mellitus: From ailing to failing
87. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans
88. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects
89. Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes
90. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells
91. Effect of pioglitazone on vascular reactivity in vivo and in vitro
92. Effects of pioglitazone on calcium channels in vascular smooth muscle
93. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect
94. Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells
95. Tumour necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life
96. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation
97. Effects of tumor necrosis factor-alpha on basal and stimulated endothelium-dependent vasomotion in human resistance vessel
98. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease
99. Changing concepts of atherogenesis
100. NIDDM as a disease of the innate immune system: Association of acute-phase reactants and interleukin-6 with metabolic syndrome X
101. C-reactive protein in offspring is associated with the occurrence of myocardial infarction in first-degree relatives
102. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease
103. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages
104. PPARalpha activators inhibit tissue factor expression and activity in human monocytes
105. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator activated receptor-gamma activators
106. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
107. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction
108. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
109. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma
110. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
111. Macrophages in human atheroma contain PPARgamma: Differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro
112. Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo
113. Peroxisome proliferator-activated receptors in macrophage biology: Friend or foe?
114. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
115. Membrane transport of long-chain fatty acids: Evidence for a facilitated process
116. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice
117. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCAI pathway
118. Peroxisome proliferator-activated receptors in endothelial cell biology
119. CD36, insulin resistance, and coronary heart disease
120. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes
121. The insulin resistance syndrome: Impact on lipoprotein metabolism and atherothrombosis
122. Triglycerides, fatty acids and insulin resistance-hyperinsulinemia
123. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: Results from the 11-year follow-up of the Paris Prospective Study
124. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes
125. Lipids and lipeproteins as coronary risk factors in non-insulin-dependent diabetes mellitus
126. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM
127. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus
128. Comparison of effects of thiazolidinediones on cardiovascular risk factors: Observations from a clinical practice
129. Regulation of triglyceride metabolism by PPARs: Fibrates and thiazolidinediones have distinct effects
130. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes
131. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records
132. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone
133. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects
134. Troglitazone and small low-density lipoprotein in type 2 diabetes
135. Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers
136. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients
137. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: Pleiotropic effects on CD36 expression and HDL
138. Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes
139. Pioglitazone hydrochloride inhibits cholesterol absorption and lowers plasma cholesterol concentrations in cholesterol-fed rats
140. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives
141. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus
142. Cardiac and glycemic benefits of troglitazone treatment in NIDDM
143. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone
144. Pioglitazone attenuates diet-induced hypertension in rats
145. Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat
146. The thiazolidinedione rosiglitazone (BRL 49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats
147. Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity
148. Effects of ciglitazone on blood pressure and intracellular calcium metabolism
149. Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes
150. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
151. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes
152. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study
153. Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes
154. Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization
155. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy
156. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells
157. Insulin sensitivity and atherosclerosis
158. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus
159. Thiazolidinediones down-regulate plasminogen activator inhibitor type I expression in human vascular endothelial cells: A possible role for PPAR gamma in endothelial function
160. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus
161. The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC-555 treatment
162. Troglitazone enhances differentiation, basal glucose uptake, and Glutl protein levels in 3T3-L1 adipocytes
163. Efficacy of troglitazone on body fat distribution in type 2 diabetes
164. Effect of troglitazone on body fat distribution in type 2 diabetic patients
165. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes
166. Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides
167. Hepatic failure in a patient taking rosiglitazone
168. Hepatocellular injury in a patient receiving rosiglitazone. A case report
169. Evaluation of liver function in type 2 diabetic patients during clinical trials: Evidence that rosiglitazone does not cause hepatic dysfunction